A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-Controlled Study of Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Pexelizumab (Primary)
  • Indications Coronary disorders; Myocardial infarction
  • Focus Therapeutic Use
  • Acronyms PRIMO-CABG-2; PRIMO-CABG-II
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 01 Jul 2011 Results published in the Journal of Thoracic and Cardiovascular Surgery.
    • 24 Mar 2009 Additional lead trial centres identified as reported by ClinicalTrials.gov.
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top